Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Selinde S. Wind; Manon A. A. Jansen; Melanie Rijsbergen; Michiel J. van Esdonk; Dimitrios Ziagkos; Wing C. Cheng; Tessa Niemeyer-van der Kolk; John Korsten; Agnieszka Gruszka; Debora Schmitz-Rohmer; David Bonnel; Raphael Legouffe; Florian Barré; Marcel W. Bekkenk; Ellen R. M. de Haas; Koen D. Quint; Harald Schnidar; Melanie Rolli; Henk Johan Streefkerk; Jacobus Burggraaf; Maarten H. Vermeer; Robert Rissmann

doi:https://doi.org/10.3390/cancers15051485

Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Selinde S. Wind, Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, David Bonnel, Raphael Legouffe, Florian Barré, Marcel W. Bekkenk, Ellen R. M. de Haas, Koen D. Quint, Harald Schnidar, Melanie Rolli, Henk Johan Streefkerk, Jacobus BurggraafMaarten H. Vermeer, Robert Rissmann

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

Original language	English
Article number	1485
Journal	Cancers
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/cancers15051485
Publication status	Published - 1 Mar 2023

Access to Document

https://doi.org/10.3390/cancers15051485

Cite this

Wind, S. S., Jansen, M. A. A., Rijsbergen, M., van Esdonk, M. J., Ziagkos, D., Cheng, W. C., Niemeyer-van der Kolk, T., Korsten, J., Gruszka, A., Schmitz-Rohmer, D., Bonnel, D., Legouffe, R., Barré, F., Bekkenk, M. W., de Haas, E. R. M., Quint, K. D., Schnidar, H., Rolli, M., Streefkerk, H. J., ... Rissmann, R. (2023). Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). Cancers, 15(5), Article 1485. https://doi.org/10.3390/cancers15051485

@article{ae101a39662645b4a391b8f8c5e2e4a1,

title = "Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)",

abstract = "The authors wish to make the following corrections to this paper [1]: 1. {\textquoteleft}Harald Schnidar{\textquoteright} was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.",

author = "Wind, {Selinde S.} and Jansen, {Manon A. A.} and Melanie Rijsbergen and {van Esdonk}, {Michiel J.} and Dimitrios Ziagkos and Cheng, {Wing C.} and {Niemeyer-van der Kolk}, Tessa and John Korsten and Agnieszka Gruszka and Debora Schmitz-Rohmer and David Bonnel and Raphael Legouffe and Florian Barr{\'e} and Bekkenk, {Marcel W.} and {de Haas}, {Ellen R. M.} and Quint, {Koen D.} and Harald Schnidar and Melanie Rolli and Streefkerk, {Henk Johan} and Jacobus Burggraaf and Vermeer, {Maarten H.} and Robert Rissmann",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = mar,

day = "1",

doi = "https://doi.org/10.3390/cancers15051485",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "5",

}

Wind, SS, Jansen, MAA, Rijsbergen, M, van Esdonk, MJ, Ziagkos, D, Cheng, WC, Niemeyer-van der Kolk, T, Korsten, J, Gruszka, A, Schmitz-Rohmer, D, Bonnel, D, Legouffe, R, Barré, F, Bekkenk, MW, de Haas, ERM, Quint, KD, Schnidar, H, Rolli, M, Streefkerk, HJ, Burggraaf, J, Vermeer, MH & Rissmann, R 2023, 'Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)', Cancers, vol. 15, no. 5, 1485. https://doi.org/10.3390/cancers15051485

Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). / Wind, Selinde S.; Jansen, Manon A. A.; Rijsbergen, Melanie et al.
In: Cancers, Vol. 15, No. 5, 1485, 01.03.2023.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction

T2 - Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

AU - Wind, Selinde S.

AU - Jansen, Manon A. A.

AU - Rijsbergen, Melanie

AU - van Esdonk, Michiel J.

AU - Ziagkos, Dimitrios

AU - Cheng, Wing C.

AU - Niemeyer-van der Kolk, Tessa

AU - Korsten, John

AU - Gruszka, Agnieszka

AU - Schmitz-Rohmer, Debora

AU - Bonnel, David

AU - Legouffe, Raphael

AU - Barré, Florian

AU - Bekkenk, Marcel W.

AU - de Haas, Ellen R. M.

AU - Quint, Koen D.

AU - Schnidar, Harald

AU - Rolli, Melanie

AU - Streefkerk, Henk Johan

AU - Burggraaf, Jacobus

AU - Vermeer, Maarten H.

AU - Rissmann, Robert

PY - 2023/3/1

Y1 - 2023/3/1

N2 - The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

AB - The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

UR - http://www.scopus.com/inward/record.url?scp=85149721907&partnerID=8YFLogxK

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149721907&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/36900424

U2 - https://doi.org/10.3390/cancers15051485

DO - https://doi.org/10.3390/cancers15051485

M3 - Comment/Letter to the editor

C2 - 36900424

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 5

M1 - 1485

ER -

Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC et al. Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). Cancers. 2023 Mar 1;15(5):1485. doi: https://doi.org/10.3390/cancers15051485

Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Abstract

Access to Document

Other files and links

Cite this